整理 | GLP1减重宝典内容团队 2026年3月3日，诺和诺德宣布其司美格鲁肽注射液的新适应症在中国已提交上市申请，并拟纳入优先审评。这一新适应症旨在治疗伴有中至重 度肝纤维化的代谢相关脂肪性肝炎（MASH）患者，特别是针对F2-F3期的非肝硬化成人患者。 司美格鲁肽的全球影响力 司美格鲁肽作为诺和诺德的旗舰药物，早在2025年8月已获得美国FDA批准，用于治疗伴有中度到重度肝纤维化的非肝硬化MASH患者，且要 求联合低热量饮食和增加体力活动。此次中国的申报，是基于ESSENCE临床试验的部分结果。该试验评估了每周一次注射2.4mg司美格鲁肽的 疗效，结果显示，司美格鲁肽在改善肝纤维化和脂肪性肝炎消退方面，均表现出优于安慰剂的统计学显著性。 临床试验结果 ESSENCE试验的第一阶段结果表明，使用司美格鲁肽的患者在改善肝纤维化和消退脂肪性肝炎方面，达到了以下临床指标： 在第72周时，36.8%的患者实现了"肝纤维化改善且无脂肪性肝炎恶化"，而安慰剂组仅为22.4%。 62.9%的患者达到了"脂肪性肝炎消退且无肝纤维化恶化"的效果，而安慰剂组为34.3%。 作为诺和诺德的明星药物，司美格鲁肽的销售表现十分亮眼 ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo's site in Monksland, Athlone, is one of 16 facilities the company has across the world. The expansion of the 45-acre tabletting facility is expected to be completed by 2028, though construction has already begun. The site's existing 260 employees will focus on delivering oral glucagon-like peptide-1 receptor agonists (GLP- 1RAs). The Danish ...

Company Strategy - Roche aims for a double-digit market share in the weight loss market, seeking to close the gap with its competitor Novo Nordisk [1] - The CEO of Roche, Thomas Schinecker, expressed the expectation to be among the top three players in the market at the very least [1]

In this articleNVOLLYNVONovo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities f ...

Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were elected for the next four years: Semsi Kilic Madsen (new)Mette Bøjer Jensen (re-elected)Elisabeth Dahl Christensen (re-elected)Désirée Jantzen Asgreen (new) The following were elected as substitutes for the employee-elected board members: Trine Hartvig KristiansenTamara SchmidtTanja VillumsenHass ...

Key Takeaways Novo Nordisk stock fell 21% after CagriSema lost to Zepbound in the phase III REDEFINE 4 obesity study.Lilly's orforglipron beat Rybelsus in ACHIEVE-3, cutting A1C by 2.2% and weight by 9.2% at 52 weeks.Novo Nordisk plans to cut U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 monthly by 2027.Novo Nordisk (NVO) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulate ...

Novo Nordisk to invest $506 million in Ireland plant expansion | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, November 24, 2025. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]COPENHAGEN, March 2 (Reuters) - Novo Nordisk [(NOVOb.CO), opens new tab] said on Monday it wi ...

Core Insights - Novo Nordisk announced a significant investment of 432 million euro (approximately DKK 3.2 billion) in its Monksland facility in Athlone, Ireland, aimed at enhancing manufacturing capacity for GLP-1 treatments [1][2]. Group 1: Investment Details - The investment represents a strategic milestone for Novo Nordisk, reinforcing its long-term commitment to Ireland and global healthcare innovation [2]. - The funding will support the upgrade and retrofit of the existing facility, enhancing capabilities for oral GLP-1 products and allowing Ireland to serve as a critical hub for markets outside the US [2][3]. Group 2: Employment and Economic Impact - The project will create up to 500 construction jobs, with construction already underway and expected to be completed gradually from the end of 2027 through 2028 [3]. - The existing workforce of 260 employees will focus on delivering high-quality oral treatments in an efficient and environmentally sustainable manner [3]. Group 3: Company Background - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and employs approximately 68,800 people across 80 countries [4]. - The company markets its products in around 170 countries, focusing on defeating serious chronic diseases through scientific breakthroughs and expanding access to medicines [4].

Novo will spend $507 million upgrading an Irish factory to produce its hit Wegovy weight-loss pill for markets outside the US https://t.co/DNsZ8zE5ti ...